# Kang Yu
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/kang-yu/
## Facts
| Field | Value |
| --- | --- |
| Citations | 1,337 |
| Field | CAR-T cell therapy research |
| h-index | 17 |
| i10-index | 30 |
| Last Known Institution | Shenyang Pharmaceutical University |
| OpenAlex ID | https://openalex.org/A5100624618 |
| ORCID iD | 0000-0002-1211-2830 |
| Works | 79 |
## Researcher papers
- [One-pot synthesis of N-doped carbon dots with tunable luminescence properties](https://scholariq.org/papers/one-pot-synthesis-of-n-doped-carbon-dots-with-tunable-luminescence-properties/)
- [N, S co-doped carbon dots with orange luminescence synthesized through polymerization and carbonization reaction of amino acids](https://scholariq.org/papers/n-s-co-doped-carbon-dots-with-orange-luminescence-synthesized-through/)
- [Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class Ι histone deacetylases](https://scholariq.org/papers/pure-curcumin-increases-the-expression-of-socs1-and-socs3-in-myeloproliferative/)
- [PEGylated Cu 3 BiS 3 hollow nanospheres as a new photothermal agent for 980 nm-laser-driven photothermochemotherapy and a contrast agent for X-ray computed tomography imaging](https://scholariq.org/papers/pegylated-cu-sub-3-sub-bis-sub-3-sub-hollow-nanospheres-as-a-new-photothermal/)
- [Low Dose of Human scFv-Derived BCMA-Targeted CAR-T Cells Achieved Fast Response and High Complete Remission in Patients with Relapsed/Refractory Multiple Myeloma](https://scholariq.org/papers/low-dose-of-human-scfv-derived-bcma-targeted-car-t-cells-achieved-fast-response/)
- [Prognostic Significance of Pretreatment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma](https://scholariq.org/papers/prognostic-significance-of-pretreatment-neutrophil-lymphocyte-ratio-and-platelet/)
- [Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial](https://scholariq.org/papers/anthracycline-dose-optimisation-in-patients-with-diffuse-large-b-cell-lymphoma-a/)
- [A Review of the Current Practice of Diagnosis and Treatment of Idiopathic Membranous Nephropathy in China](https://scholariq.org/papers/a-review-of-the-current-practice-of-diagnosis-and-treatment-of-idiopathic/)
- [Efficacy and Safety of CAR-T Therapy with Safety Switch Targeting Bcma for Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Clinical Study](https://scholariq.org/papers/efficacy-and-safety-of-car-t-therapy-with-safety-switch-targeting-bcma-for/)
- [Prognostic significance of the red blood cell distribution width in diffuse large B-cell lymphoma patients](https://scholariq.org/papers/prognostic-significance-of-the-red-blood-cell-distribution-width-in-diffuse/)
## Researcher topics
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Chronic Myeloid Leukemia Treatments](https://scholariq.org/topics/chronic-myeloid-leukemia-treatments/)
- [Viral-associated cancers and disorders](https://scholariq.org/topics/viral-associated-cancers-and-disorders/)
## Researcher university
- [Shenyang Pharmaceutical University](https://scholariq.org/institutions/shenyang-pharmaceutical-university/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.